Pipeline Insight: Breakthrough Pain - Fast-acting Players Will Capture Majority Market Share - Biologics Market Research

Pipeline Insight: Breakthrough Pain - Fast-acting Players Will Capture Majority Market Share
Published Date: November 2006
Published By: Datamonitor
Page Count: 140
Order Code: R313-18170
Price: $11,400 Online Download
$22,800 Global Site License
Introduction
In spite of generic Actiq competition, Cephalon?s reign of the breakthrough pain market will be secured in the short-term with sales of its follow-on brand Fentora. From 2008, however, a number of fast-acting analgesics will enter the arena and battle for market share; this and other growth drivers will see the market more than double from 2005 to reach an estimated $2.5 billion in 2016.
Scope
Discussion and quantification of the patient potential and market size of breakthrough pain in both malignant and non-malignant diseases
Assessment of the unmet clinical needs in breakthrough pain as validated by interviewed international opinion leaders
Detailed overview and assessment of key drugs in Phase II and above clinical development, including Fentora, Rapinyl, and BEMA Fentanyl
Ten-year sales forecasts to 2016 for key pipeline products
Highlights
Relatively high unmet clinical need, additional patient groups, the launch of new products, and no further key patent expiries within the next ten years will see the breakthrough pain market more than double from 2005 to reach $2.5 billion in 2016.
As well as for oral transmucosal fentanyl products, opportunities also exist for non-oral analgesics. Intranasal and inhaled technology may provide convenient and fast acting analgesia and are potentially suitable for self-administration in the lucrative outpatient setting.
A key growth strategy will be to gain initial approval for cancer breakthrough pain and then drive sales in additional indications through off-label use or regulatory approval. Key non-malignant applications for fast acting analgesics include breakthrough pain in post-operative pain, chronic low back, and osteoarthritic pain.
Reasons to Purchase
Explore the strategies that have made Cephalon the market leading company in breakthrough pain
Examine the potential for intranasal and inhaled analgesics and what other factors companies are using to differentiate their products
Analyze the competitive environment at the time of product launch and identify lucrative gaps in the market